Thermo Fisher Scientific has received FDA clearance for its de novo submission of the Thermo Scientific QMS Plazomicin Immunoassay, the first of its kind for complementary diagnostic immunoassays.

This quantitative immunoassay measures the concentration of a novel therapeutic antibiotic, plazomicin, using the automated clinical chemistry analyzer, Beckman Coulter AU 680. Plazomicin (trade name ZEMDRI1) is a next-generation aminoglycoside being used to treat patients with complicated urinary tract infections (cUTI).

The new QMS Plazomicin Immunoassay is the latest addition to the Thermo Fisher line of therapeutic drug monitoring (TDM) immunoassays, which employ proprietary technology across a range of drug classes including those for antibiotics, antiepileptics, antiarrhythmics, immunosuppressants, and others.

Thermo Scientific TDM immunoassays enable physicians to monitor and administer therapeutics on an individual patient basis. By maintaining optimized drug levels, the effects of under or over dosage may be minimized and patient outcome improved.

This immunoassay was developed in collaboration with Achaogen, Inc., a biopharmaceutical company with expertise in innovative antibacterial drug development to address multi-drug resistant (MDR) gram-negative infection.